985 Clinical efficacy and safety of combined house dust-mite subcutaneous immunotherapy (HDM -SCIT) and omalizumab in five cases of allergic rhinitis & asthma TARGET is based on real world prescription data and demonstrates the effectiveness of authorized MCT-adsorbed allergoids on AR in clinical practice routine. This was also shown for the entire AIT group.Ĭonclusion: Real world evidence studies add important information about the effectiveness of AIT under natural conditions.
#Settings for ross carbonite media wipe free#
control group were AR treatment free in the follow up period. After the end of the treatment (and expiry of the last prescription) statistically significant more patients treated with MCT-adsorbed allergoids (with AR at baseline) vs. Patients with at least four prescriptions of the focus products within three years from index date were included into the study. Results: Within the index-period (09/2009–08/2013) 181.496 patients aged between 5 and 65 years received prescriptions within the AIT group (all three preparations). The progression of AR is measured by the prescription of symptomatic medication. control group (patients not receiving AIT). One objective of the TARGET study program is to assess the impact of authorized pollen SCIT allergoids (MCT-adsorbed allergoid, allergoid 2, allergoid 3) on allergic rhinitis (AR) patients vs. The information collected is patient related with a unique anonymized identification number, allowing a patient follow up over time. It accesses prescription data of German patients within the statutory health insurance system (GKV). Method: TARGET is designed as a retrospective cohort study and is based on the IMS ® LRx database (IQVIA, Germany). The aim of the ‘ Tyrosine- Allergoid – Real World Evidence in Germany – Effectiveness in AI T” (TARGET) study program is to investigate the “effectiveness” of authorized MicroCrystalline Tyrosine (MCT)-adsorbed grass and tree pollen (pollen) SCIT allergoids in clinical practice routine. However, the treatment outcomes always reflect the effects under artificial conditions. The safety profile of SCIT allergoids is favorable and the efficacy has been proven in DBPC trials and meta analysis for various preparations. 994 TARGET - impact of authorized microcrystalline tyrosine (MCT)-adsorbed pollen SCIT allergoids on allergic rhinitis (AR) under real life conditionsġDepartment of Pediatric Pneumology and Allergology, University Hospital Carl Gustav Carus, Dresden, Germany 2Department of Otolaryngology, Head and Neck Surgery, University of Tuebingen, Tuebingen, Germany 3Center for Rhinology and Allergology, Wiesbaden, Germanyīackground: Subcutaneous immunotherapy with allergoid preparations (SCIT allergoids) represent the market leading application route in allergen immunotherapy (AIT) in Germany.
0 kommentar(er)
